Morningstar

Smith & Nephew PLC SN.

Morningstar Rating
Unlock
Stock XLON Rating as of
GBX 1,131.50 −5.50 (0.48%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Smith & Nephew: Turnaround Is Taking Hold, and New Products Should Support Moat

Debbie S. Wang

Now that Smith & Nephew has made gradual and steady progress on improving its operations since CEO Deepak Nath came aboard, we’ve taken another look at its newer technologies that we think should help support its narrow moat over the longer term. We are leaving our fair value estimate unchanged. While we remain pessimistic about the firm’s ability to wrestle large joint reconstruction market share away from larger rivals such as Stryker, Zimmer Biomet, and Johnson & Johnson, we are more optimistic about Smith & Nephew’s products in other therapeutic areas.

Read Full Report

Price vs Fair Value

View History
SN. is trading at a 861% premium.
Price
GBX 1,131.50
Fair Value
GBX 6,363.00
Uncertainty
Medium
1-Star Price
GBX 1,486.20
5-Star Price
GBX 6,273.90
Economic Moat
Bgqqwn
Capital Allocation
Tqhftnwk

Bulls Say, Bears Say

Bulls

Smith & Nephew participates in the fast-growing sports medicine arena thanks to its extensive arthroscopy portfolio.

Bears

Smith & Nephew's attempted shift to the lower-cost Syncera distribution model in the U.S. was disappointing, which leaves the firm in a tenuous competitive position for large joint replacement.

Show More

News

View All

Trading Information

Previous Close Price
GBX 1,137.00
Day Range
GBX 1,130.33–1,149.00
52-Week Range
GBX 887.00–1,245.26
Bid/Ask
GBX 1,090.50 / GBX 1,150.00
Market Cap
GBX 986.64 Bil
Volume/Avg
2.4 Mil / 2.3 Mil

Key Statistics

Price/Earnings (Normalized)
15.10
Price/Sales
2.20
Dividend Yield (Trailing)
2.68%
Dividend Yield (Forward)
2.68%
Total Yield
2.68%

Company Profile

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Mid Core
Total Number of Employees
18,000
Website
https://www.smith-nephew.com

Competitors

Valuation

View More
Metric
SN.
SYK
JNJ
Price/Earnings (Normalized)
 15.1032.1815.40
Price/Book Value
 2.406.975.43
Price/Sales
 2.206.504.58
Price/Cash Flow
 13.1530.6717.42
Price/Earnings
SN.
SYK
JNJ

Financial Strength

Metric
SN.
SYK
JNJ
Quick Ratio
 1.110.810.77
Current Ratio
 2.511.681.07
Interest Coverage
 3.0912.2824.45
Quick Ratio
SN.
SYK
JNJ

Profitability

Metric
SN.
SYK
JNJ
Return on Assets (Normalized)
 7.37%11.13%13.17%
Return on Equity (Normalized)
 14.30%23.26%32.42%
Return on Invested Capital (Normalized)
 10.12%14.77%20.93%
Return on Assets
SN.
SYK
JNJ

Medical Devices Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
TgccldfqHnzwhxx$196.1 Bil
 Stryker Corp
SYK
PtcysdzvfJlqx$137.7 Bil
 Boston Scientific Corp
BSX
NclnmcfTznczv$122.3 Bil
 Medtronic PLC
MDT
HxzqlmnntGncqj$114.7 Bil
 Edwards Lifesciences Corp
EW
YrszzqrjLdgsz$39.6 Bil
 Koninklijke Philips NV ADR
PHG
TzntsWqfb$29.3 Bil
 DexCom Inc
DXCM
XszzsdyvhmQhxw$27.1 Bil
 Steris PLC
STE
BjdzfhxmZsxxn$23.3 Bil
 Zimmer Biomet Holdings Inc
ZBH
XtnlsvphqNyh$21.9 Bil
 Insulet Corp
PODD
VvthtrcqzXvgcjnc$16.5 Bil

Sponsor Center